LIDEX-E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIDEX-E (LIDEX-E).
LIDEX-E (fluocinonide) is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. |
| Excretion | Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine; negligible biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 3.5 hours; clinical context: steady-state achieved rapidly with bid dosing, suitable for short-term use. |
| Protein binding | Greater than 99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Volume of distribution approximately 1.4 L/kg; indicates extensive tissue penetration and distribution into peripheral compartments. |
| Bioavailability | Topical: Bioavailability is variable, estimated at 1-36% depending on skin condition and site; negligible systemic bioavailability from intact skin, increased with damaged skin. |
| Onset of Action | Topical: Onset of vasoconstrictor effect within 1 hour; clinical improvement may be seen within 12-24 hours. |
| Duration of Action | Topical: Duration of vasoconstriction 4-6 hours; clinical duration of anti-inflammatory effect typically 12-24 hours, requiring twice-daily application. |
| Molecular Weight | 494.53 |
Apply a thin film to affected area 1-4 times daily; topical; do not use occlusive dressings.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required; topical administration with negligible systemic absorption. |
| Liver impairment | No dose adjustment required; topical administration with negligible systemic absorption. |
| Pediatric use | Apply a thin film to affected area 1-2 times daily; avoid prolonged use and occlusive dressings. Limit quantity to lowest effective dose due to increased systemic absorption risk. |
| Geriatric use | Use with caution; apply sparingly to affected area 1-2 times daily. Avoid prolonged use and occlusive dressings due to increased skin atrophy risk. |
| 1st trimester | Avoid use during first trimester unless benefit outweighs risk; topical corticosteroids are generally preferred with lowest potency and shortest duration. |
| 2nd trimester | Use with caution; limited data suggest no increased risk of major malformations with topical use, but prolonged use may lead to fetal growth restriction or adrenal suppression. |
| 3rd trimester | Avoid prolonged use or high potency formulations near term due to potential for fetal adrenal suppression and low birth weight. |
Clinical note
Comprehensive clinical and safety monograph for LIDEX-E (LIDEX-E).
| Placental transfer | Fluocinonide is a corticosteroid; systemic absorption after topical application is generally low but can cross placenta. Degree of transfer depends on application site, integrity of skin, and duration of use. Limited data quantify transfer in humans. |
| Breastfeeding | Topical application to small areas, especially if not on the nipple, is likely compatible with breastfeeding. However, avoid application to the breast or nipple to prevent infant ingestion. Use the lowest potency for the shortest duration. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to fluocinonide or any component of the formulationUntreated bacterial, fungal, viral, or parasitic skin infectionsPerioral dermatitisRosaceaVulvovaginal candidiasisAcne vulgaris
| Precautions | Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, and hyperglycemia, Prolonged use, use on large areas, occlusive dressings, or in pediatric patients increases risk, Avoid use on face, axillae, or groin without medical supervision |
| Food/Dietary | No known food interactions. Avoid alcohol if using near occlusive dressings or if skin irritation occurs. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used appropriately during pregnancy. However, high potency corticosteroids, such as fluocinonide (the active ingredient in LIDEX-E), should be used with caution, especially in the first trimester. Prolonged or extensive use may increase the risk of fetal growth restriction and adrenal suppression. No specific teratogenic effects have been consistently reported in humans, but animal studies have shown an increased risk of cleft palate and other malformations with systemic exposure. Therefore, use the lowest effective potency, minimal quantity, and shortest duration possible. |
| Fetal Monitoring | Monitor maternal adrenal function if used long-term or over large body surface areas. Fetal growth and well-being should be assessed with serial ultrasound if used extensively or for prolonged periods. No specific fetal monitoring is required for short-term, limited use. |
| Fertility Effects | No specific studies on the effect of topical fluocinonide on fertility have been conducted. However, systemic corticosteroids can affect hormonal balance and menstrual cycles. Based on the low systemic absorption of topical application, it is unlikely to significantly impact fertility. |
| Clinical Pearls |
| LIDEX-E (fluocinonide 0.05% emollient cream) is a high-potency corticosteroid. Avoid use on face, groin, axillae, or for more than 2 weeks continuously. Monitor for skin atrophy and HPA axis suppression with long-term or widespread use. Use with caution in patients with impaired skin integrity or infections. |
| Patient Advice | Apply a thin layer to affected areas only, gently rubbing in. · Do not use on broken skin, face, or genital area without doctor's direction. · Wash hands after application unless treating hands. · Avoid covering treated area with bandages or wraps unless instructed. · Do not use longer than prescribed; overuse can cause thinning of skin or adrenal gland suppression. · Inform doctor if condition worsens, does not improve after 2 weeks, or if signs of infection occur. |